Company intelligence / Profile preview
Thetis Pharmaceuticals
Branford, Connecticut (CT), United Statesthetispharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TP-317 is a first-in-class oral small molecule drug candidate based on Resolvin E1 that selectively engages the BLT1 receptor to promote tissue repair and restore immune homeostasis. It has demonstrated safety and tolerability in a Phase 1a single ascending dose study in healthy volunteers. Preclinical data show gut barrier protection, inflammation reduction, pain relief for IBD indications; also promising anti-tumor activity alone or combined with immunotherapy or chemotherapy in solid tumors. New data presented at ECCO 2025 further validate its mechanism of action[6][8][9].
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Small molecule drugs derived from bioactive lipids called Resolvins, specifically Resolvin E1-based compounds
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Thetis Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thetis Pharmaceuticals.